Unjha Formulations share price
You have to be logged in to add this to Watchlist.- ₹22.70(-1.18%)April 17, 2025 15:10:32 PM IST
- NSE
- BSE
- Vol : 0.16K (NSE + BSE)Last 20 day avg : 1.77 K
Unjha Formulations is trading -1.18% lower at Rs 22.70 as compared to its last closing price. Unjha Formulations has been trading in the price range of 22.75 & 22.25. Unjha Formulations has given -25.26% in this year & 2.48% in the last 5 days. Unjha Formulations has TTM P/E ratio 21.40 as compared to the sector P/E of 47.75.The company posted a net profit of 0.22 Crores in its last quarter.Listed peers of Unjha Formulations include Decipher Labs (3.36%), Beryl Drugs (4.60%), Unjha Formulations (-1.18%).The Mutual Fund holding in Unjha Formulations was at -% in . The MF holding has - from the last quarter. The FII holding in Unjha Formulations was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 19, 2025, 09:46 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/B3.72The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values15.99Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility-0.35Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 32.15% from Rs 5.55 crore to Rs 3.76 crore, year-on-year- The company's profit declined by 42.33% year-on-year during the December quarter, dropping from Rs 0.39 crore to Rs 0.22 crore
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 24.26
- R2
- 26.69
- R3
- 28.75
- S1
- 19.77
- S2
- 17.71
- S3
- 15.28
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Decipher Labs | Neutral | 11.68 | 3.36 | 11.80 | - | 0.54 | - | - |
| Beryl Drugs | Moderately Bearish | 22.72 | 4.60 | 11.52 | 15.15 | 1.29 | - | 26.94 |
| Unjha Formulations | Neutral | 22.70 | -1.18 | 10.17 | 36.60 | 3.72 | - | - |
| Vivanza Biosciences | Neutral | 2.34 | 0.43 | 9.36 | 16.71 | 2.02 | - | 57.82 |
| Ortin Global | Moderately Bearish | 11.00 | - | 8.94 | - | 3.23 | - | 63.82 |
- Promoter(s) holding is moderate at 36.92%
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-03-17 | Others |
| 2025-02-04 | Quarterly Results |
| 2024-11-08 | Quarterly Results |
| 2024-08-01 | Quarterly Results |
| 2024-05-17 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE576D01015
- BSE Code531762
- NSE Code
Unjha Formulations is trading at 22.70 as on Thu Apr 17 2025 09:40:32. This is -1.18% lower as compared to its previous closing price of 22.97.
The market capitalization of Unjha Formulations is 10.17 Cr as on Thu Apr 17 2025 09:40:32.
The 52 wk high for Unjha Formulations is 39.00 whereas the 52 wk low is 18.25
Unjha Formulations can be analyzed on the following key metrics -
- TTM P/E: 21.40
- Sector P/E: 47.75
- Dividend Yield: 0.00%
- D/E ratio: -
Unjha Formulations reported a net profit of 0.28 Cr in 2024.